Cougar`s surmises chicago white sox oncology portfolio baseball ticket states includes CB7630, atargeted inhibitor of the 17-alpha hydroxylase/c17,20 lyase enzyme, which iscurrently being studied in two Phase III clinical trials in prostate cancer anda Phase I/II trial in breast cancer; CB3304, an inhibitor of microtubuledynamics, which is currently in a Phase I trial in multiple myeloma; and CB1089,an analog of vitamin D, which has been clinically tested in a number of solidtumor types. is a Los Angeles-based biotechnology companyestablished to in-license and develop clinical stage drugs, with a specificfocus on the field of oncology. These patient groups continue to represent patientpopulations that are underserved with current treatments." About Cougar Biotechnology, Inc.Cougar Biotechnology, Inc. These populations not only representsignificant unmet medical needs in prostate cancer but also are representativeof the patient populations being studied in our ongoing Phase III trials(COU-AA-301 and COU-AA-302)." Arturo Molina, M.D., M.S., FACP, Chief Medical Officer and Executive VicePresident of Clinical Research and Development of Cougar, added, "We are pleasedto present the multi-center results of these Phase II studies, which continue tosupport the potential roles of CB7630 both as a second-line hormonal therapy forpatients with advanced prostate cancer who fail first-line hormonal treatmentand as a second-line therapy for patients with advanced prostate cancer who faildocetaxel-based chemotherapy. CB7630 continues to show strong evidence of antitumor activityin patients with chemotherapy-naïve disease as well as in patients withchemotherapy-refractory disease.

Auerbach, Chief Executive Officer and President of Cougar Biotechnology,said, "We are pleased to present data from these clinical trials at the ASCOAnnual Meeting chicago white sox email . Furthermore, for the27 patients who had been previously treated with ketoconazole, the median timeto PSA progression was estimated to be 99 days (14 weeks) Alan H baseball stuff . For the 31patients who had not received prior treatment with ketoconazole, the median timeto PSA progression was estimated to be 198 days (28 weeks) cubs rooftop . Of the 18 evaluable patients with measurable tumor lesions, 3 patients (17%)experienced confirmed partial radiological responses (as measured by the RECISTcriteria) and 11 patients (61%) experienced ongoing stable disease world baseball series . Furthermore, of the 27 patients who had been previously treated withketoconazole, 7 patients (26%) experienced a confirmed decline in PSA levels ofgreater than 50%.

Of the 31 patients who had not received prior treatment with ketoconazole,13 patients (42%) experienced a confirmed decline in PSA levels of greater than50% chicago white sox ringtones . After 12 weeks of treatment, 20patients (34%) experienced a confirmed decline in PSA levels of greater than50% baseball blog . The combination of CB7630 plus prednisone was well tolerated with only minimaltoxicity in this post-docetaxel population chicagowhitesox net email . Additionally, 27 patients(47%) had been previously treated with ketoconazole, a drug that is currentlyused off-label as a secondary hormonal therapy baseball ticket .

Of the 58 patients, 13 patients (22%) had visceral disease, 26 patients (45%)had bone and soft tissue metastases, 11 patients (19%) had bone metastases onlyand 8 patients (14%) had soft tissue metastases only jake peavy . To date, a total of 58 patientshave been enrolled in the trial at 8 different centers baseball stuff . In the trial, CB7630 in combination withprednisone is administered orally, once daily, to patients with CRPC who havefailed treatment with androgen deprivation therapy and have failed treatmentwith first-line docetaxel-based chemotherapy cubs rooftop . The COU-AA-004 Phase II trial is being conducted at numerous locations in theUnited States and United Kingdom . Daniel Danila from MemorialSloan-Kettering Cancer Center presented data from the ongoing Phase II trial ofCB7630 in combination with prednisone in patients with advanced prostate cancerwho have failed androgen deprivation and docetaxel-based chemotherapy(COU-AA-004).